Cartilage+OA Flashcards

1
Q

What fraction of people above 45yrs seek treatment for OA?

A

1/3
-81% of these have constant pain or functional limitations
-7.5 million working days lost per year in UK
-OA pain is the commonest reason for joint replacement
-USA: predicted 0.5M hip replacements each year by 2030

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the commonest reason for joint replacement?

A

OA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is shown in this arthroscopy?

A

A chondral defect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What components make up the cartilage ECM and what are 2 of their functions?

A

Aggrecan(type of proteoglycan)-Resist compression
T2 collagens-High tensile strength
Water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Outline the function of the chondrocyte

A

<5% tissue
Producer and degrader of the cartilage matrix
Highly metabolically active
Exist in relative hypoxia
Interactions with matrix: growth factors, mechano-transduction
No cell division after adolescence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Give the 4 layers of hyaline cartilage including the location of the tide mark

A

Superficial layer
Transitional/Intermediate
Deep/Radial
(Tide mark)
Calcified
——-Bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What type of enzyme breaks down collagen?

A

Collagenases-A type of metalloproteinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which metalloproteinase are useful for breaking down collagen?

A

MMPs-3,11,18

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What type of molecule is MMP-3?

A

A stromelysin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Outline the structure of aggrecan

A

Sugar chains off of a protein backbone, attached to hyaluronan, contains 3 major domains
-Branches of keratin sulphate and chondroitin sulphate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Where can aggrecan be cleaved and by what?

A

Matrix metalloproteinases between amino acids 341-342

Aggrecanases between amino acids 373-374

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the intrinsic anabolic/anti-catabolic factors for articular cartilage?

A

TIMPs (Tissue Inhibitor of Metalloproteinases) 1-4
Growth factors e.g. fibroblast growth factor (FGF-2), Insulin-like growth factor (IGF), Transforming growth factor (TGF)-β, activin A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the extrinsic anabolic/anti-catabolic factors for articular cartilage?

A

Hormones e.g. testosterone, estrogen
Some drugs e.g. FGF-18

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Simply, why does cartilage matrix loss occur?

A

Excessive degradation compared to repair

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What part of your knee supports most of the weight?

A

The medial compartment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What occurs if your joints are absent of mechanical load?

A

You can’t maintain cartilage thickness and turnover, leading to cartilage atrophy

17
Q

How much more load is there through the tibiofemoral joint of the knee compared to standing with:
Walking
Jumping
Running
Climbing stairs

A

Walking – 2-6 X body weight
Jumping – 7-9 X body weight
Running – 3-8 X body weight
Climbing stairs – 3-10 X body weight

18
Q

Describe the pathogenesis of OA

A

Inflammation
Repair/remodelling of the cartilage
Pain

19
Q

What occurs to the matrix components of cartilage in OA pathology

A

Proteoglycan-Fragmented by aggrecanases
Water-Increased by initial swelling, then lost
Collagen-Broken down by collagenases

20
Q

Describe the pathology of EARLY OA

A

-Loss of proteoglycans
-Fibrillation of tissues

21
Q

Features of established OA that early OA doesn’t have?

A

Established has:
-Fissuring
-Partial/full thickness cartilage loss
-Osteophytes, bone cysts, synovial inflammation

22
Q

What are the risk factors for OA?

A

Age
Obesity
Mechanicals:Joint injury, joint misalignment
Genetics
Chondrodysplasias(e.g stickler syndrome)
Secondary joint damage due to inflammatory arthropathies e.g. rheumatoid arthritis

23
Q

What percent of meniscal/ACL tear victims will develop OA in the next 5-10 years

A

~50%

24
Q

Give some evidence for mechanical factors influencing the development of OA

A

Destabilising joint injuries increase risk of OA
Intra-articular fracture increases the risk of OA

25
Q

Why does lack of aggrecanase stop the loss of cartilage after joint injury?

A

Cartilage is a biologically active process, dependent on aggrecanases

26
Q

Outline the 2 pathways that lead to symptomatic OA

A

Abnormal joint + Normal load
Normal joint + Abnormal load
Leads to mechanical injury, leading to incorrect remodelling of cartilage
Then symptomatic OA

27
Q

Do all OA cases progress?

A

No, some can remain at the same severity, or even remise

28
Q

Demographically with age and sex where is OA more prevalent?

A

With greater age and more in women

29
Q

Why are OA rates increasing?

A

Higher obesity levels, poorer diets that aren’t equipped to maintain cartilage health

30
Q

How is OA diagnosed?

A

Clinically:
Stiffness
Pain on function
Crepitus, bony deformity

X-ray:
Osteophytes
Joint space narrowing
Bone cysts

Blood tests:
Normal CRP
Negative tests for RA
Other tests to exclude secondary causes

31
Q

What are these?

A

Heberdens’ nodes, diagnostic of hand OA

32
Q

Give 3 surgical options for OA treatment

A

Total joint replacement /‘arthroplasty’(hip or knee) is a highly effective treatment (best results when pain high, function poor, over 60, end stage radiographic disease)

Uni-compartmental replacement for the knee is possible

Trapeziectomy (removal of a thumb bone) is a good surgical treatment for base of thumb OA

33
Q

Outline 2 new drugs targeted at treating OA and their effects

A

SyMOADs(Symptom modifying OA drug)-Treat pain+Improve function

DMOADs(Disease modifying OA drug)-Prevent/Slow early onset of OA

34
Q

What are 3 requirements for clinical trials of new OA drugs

A

-Find drugs targeting the right sites
-Using the right population(Subgrouping+)
-Using the right outcome measurements(Imaging+patient reported outcomes)